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ABBREVIATIONS 
GWAS = genome-wide association study 
NMSC = non-melanoma skin cancer 
 SCC = squamous cell carcinoma 
 BCC = basal cell carcinoma 
 PRS = polygenic risk score 
pT = p-value threshold 
PCA =principal components analysis 
1KG3 =1000 Genomes Phase 3 
CI = confidence interval 
RE model = Random effects model 
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OR = odds ratio 
HR= hazards ratio 
SE =standard error 
Padj=approximate adjusted p value 
Pbon=Bonferroni corrected p value 
 
ABSTRACT 
Renal transplant recipients have an increased risk of non-melanoma skin cancer (NMSC) compared 
to in the general population.  Here, we show polygenic risk scores (PRS) calculated from genome-
wide association studies (GWAS) of NMSC in general, non-transplant setting, can predict risk of, and 
time to post-transplant skin cancer. Genetic variants, reaching pre-defined p-value thresholds were 
chosen from published squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) non-transplant 
GWAS. Using these genome-wide association studies, BCC and SCC PRS were calculated for each 
sample across three European-ancestry renal-transplant cohorts (n=889) and tested as predictors of 
case:control status and time to NMSC post-transplant. BCC PRS calculated at p-value threshold 1x10
-
5
 was the most significant predictor of case:control status of NMSC post-transplant (OR=1.65; 
adjusted P=0.0008; AUC(full model adjusted for clinical predictors and PRS)=0.81). SCC PRS at p-
value threshold 1x10
-5
 was the most significant predictor of time to post-transplant NMSC (adjusted 
P=8.15x10
-7
; HR=1.42, concordance (full model)=0.74). PRS of non-transplant NMSC is predictive of 
case:control status and time to NMSC post-transplant. These results are relevant to how genomics 
can risk stratify patients to help develop personalised treatment regimens. 
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1. INTRODUCTION 
Renal transplantation is an effective therapy for end-stage kidney failure, with one-year graft 
survival rates of between 89 and 91% for deceased donor grafts and graft half-life of 8.8 years in the 
United States
1,2
. As a result of this success, malignancy is a common transplant complication, with 
non-melanoma skin cancers (NMSC) accounting for 95% of post-transplant malignancies
3
. Renal 
transplant recipients have an estimated prevalence of NMSC ranging from 2%-18%
4
 and an 
approximate 16-fold excess risk of developing basal cell carcinoma (BCC), and 65-fold increased risk 
of developing squamous cell carcinoma (SCC) relative to age-matched non-transplanted individuals
5
. 
A number of studies have evaluated clinical predictors of NMSC post-transplant 
6-8
 and robust 
predictors include age, sex and type of immunosuppressive treatment
6,8,9
.  
 
The immunosuppressive regime chosen for a patient can have a dramatic effect on their risk of 
developing skin cancer, as immunosuppressants can impair the immune system’s ability to scan for 
potentially oncogenic cells. Certain classes of immunosuppressant drugs have additional 
carcinogenic properties beyond their effects on the immune system
9
. For example, it has been 
suggested that azathioprine exposure when combined with UV light induces DNA damage, which can 
lead to tumorigenesis
9
. Conversely, mammalian target of rapamycin (mTOR) inhibitors, which is also 
used as an immunosuppressant in solid organ transplants, were reported to reduce skin cancer 
incidence post-transplantation
10
.  
 
Despite the increased risk of skin cancer, only one study has tested for germline genetic associations 
with skin cancer post-transplant on a genomic scale
7
. Studying SCC in a kidney and heart transplant 
population, the authors highlighted increased age and azathioprine exposure as risk factors for skin 
cancer, but no genome-wide significant genetic predictors were detected
7
. This study had limited 
power (n=388 cases) compared to GWAS of SCC and BCC in non-transplant populations (n=8058+) 
where robust genetic risk factors for NMSC were identified
11-14
.  
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The genetic architecture of NMSC in a transplant setting would appear to mirror that of complex 
human traits generally, where common genetic variants individually tend to have small effect sizes 
and limited clinical relevance, with some notable exceptions
15,16
. However, by combining effect sizes 
across variants one can create an overall ‘polygenic risk score’ (PRS)17 which might produce a more 
clinically relevant measure of genetic load for a given trait. For the purpose of this study, PRS was 
defined as the sum of all alleles associated with a trait weighted by the effect size of that allele as 
determined by a previous GWAS. 
 
Here we set out to leverage large, robust published GWAS, to develop a PRS of NMSC and test for 
ability to predict in a transplant setting, case-control status and time to developing NMSC.  
2. MATERIALS AND METHODS  
Written, informed consent was obtained from each participant in the study. Approval for ethics 
study protocols was received from appropriate review committees. 
2.1 Cohort 
Data on post-kidney transplant recipients was collected from Tennessee (Vanderbilt University 
Medical Centre, n=275), Dublin (Beaumont Hospital, n=280), Glasgow (Western Infirmary Glasgow, 
n=64) and Belfast (Belfast City Hospital, n=270). For the Dublin and Belfast cohorts, NMSC status was 
taken from de-identified National Cancer Registry Records. For the Tennessee cohort, NMSC status 
was retrieved from de-identified electronic medical records
7
. For the Glasgow cohort, cases were 
retrieved from hospital records. Due to the small case numbers in Glasgow (n-cases=4), these 
samples were merged with the Dublin cohort for further analyses. 
 
Analysis was carried out on three phenotypes in our post-transplant cohorts: SCC, BCC and any 
NMSC. A number of individuals reported NMSC but did not have a specific sub-type recorded. Such 
individuals were included in the any NMSC analysis but not the BCC or SCC analyses.  For the Cox 
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analysis (see statistical analyses section below), cases were defined as those who developed NMSC 
post-transplantation; controls are those who have no record of NMSC post-transplantation. Controls 
were censored at last known follow-up, date of renal allograft failure or patient death. For the 
logistic regression (see below), cases were defined as those who developed NMSC within ten years’ 
post-transplantation. Controls had to be at least ten years’ cancer free post-transplantation. This 
cut-off was selected as it incorporated previously reported peak incidence rates of NMSC post-
transplant whilst still allowing for a sufficient control group in the three cohorts 
5
. If individuals 
developed both SCC and BCC post-transplant, for the any NMSC Cox analysis – time to the first 
incidence of either was taken as the time of event. For the subtype analysis, time to the specific BCC 
or SCC event was taken as the time of event. Controls in the subtype (BCC and SCC) analysis had to 
be free of any NMSC post-transplant. 
 
Exclusion criteria were as follows: non-European individuals as determined via principal components 
analysis (PCA, see below), related individuals (one from each pair of individuals with PIHAT score 
>0.1 removed) and individuals who had any incidence of any type of NMSC prior to transplant. 
Azathioprine exposure, era of transplantation (pre-2000 vs. post-2000), age at transplantation and 
sex of recipient were tested as predictors of post-transplant NMSC status. Azathioprine exposure 
data was unavailable for the Belfast cohort. Individuals in the Tennessee cohort were on an oral 
immunosuppressive regimen of calcineurin inhibitor (predominantly tacrolimus) with 38 on 
azathioprine in addition to tacrolimus
7
. In the Belfast cohort, 199 individuals received cyclosporin A 
and six individuals received tacrolimus (73 individuals had missing immunosuppression data). In the 
Dublin/Glasgow cohort, 330 individuals received cyclosporin A and eleven individuals received 
tacrolimus with 278 exposed to azathioprine. The majority of the Tennessee cohort were 
transplanted post-2000 (n=220), with 47 being transplanted between 1990-2000 and eight patients 
transplanted pre-1990, with the year of transplant ranging from 1970 to 2011. In the Belfast cohort, 
the year of transplant ranged from 1986 to 2004 with 54 patients transplanted post-2000, 153 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
patients between 1990-2000 and 63 individuals being transplanted pre-1990. In the Dublin/Glasgow 
cohort, 13 individuals were transplanted pre-1990, 266 individuals were transplanted between 
1990-2000 and 65 individuals were transplanted post 2000 with the year of transplant ranging from 
1981 to 2006. 
 
2.2 Genotyping, imputation and data quality control 
Belfast and Glasgow samples were genotyped using the Illumina® 660K array as part of the UK and 
Ireland Renal Transplant Consortium (ukirtc.org) and the Wellcome Trust Case Control Consortium 3 
Study into Renal Transplant Dysfunction
18
. Genotyping details for the Dublin and Tennessee cohorts 
were described previously
7,19
.   
 
Tennessee, Dublin and Glasgow datasets were imputed using Impute2 and the 1000 Genomes Phase 
3 (1KG3) and Genomes of the Netherlands version 5 reference panels as previously described
20-24
. 
The Belfast dataset was phased and imputed via the Sanger Imputation Service using Eagle, PBWT, 
and 1KG3-reference panel
25-28
. SNP2HLA and the Type 1 Diabetes Genetic Consortium were used to 
impute HLA alleles for each cohort
29,30
.   
Imputed genotype probabilities were converted to hard-called genotypes using PLINK (Chang et al., 
2015). Calls with uncertainty greater than 0.05 were excluded using the hard-call threshold function. 
Variants with missingness >5%, info scores <0.95, minor allele frequency <0.05 and Hardy Weinberg 
p<1x10
-6
 were removed. PCA was performed using GCTA to identify population outliers
31
 and to 
control for population structure. PC (principal component) 1 and 2 were plotted using ggplot2 in R 
and outliers were identified
32
. To identify non-European descent individuals, each of the datasets 
was merged with the Human Genome Diversity Project (HGDP) dataset
33
 and PCs were calculated 
and plotted. Individuals that did not plot to the same region as the HGDP European groups were 
removed. 
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2.3 Polygenic risk scores 
PRS was defined as the sum of all alleles associated with a trait weighted by the effect size of that 
allele as determined by a previous GWAS
17
. SNPs and associated effect sizes (in this case, log OR) 
that reached pre-defined p-value thresholds (pT; 0.0001, 1x10
-5
, 1x10
-6
, 1x10
-7
, 1x10
-8
, 1x10
-9
) were 
extracted from the discovery GWAS results data from two previously published GWAS papers, one of 
SCC
13
 and one of BCC, both in a non-transplant population
14
. The full set of discovery SNPs and 
associated effect sizes needed for calculating the PRS can be accessed via 23andme. For more details 
on accessing this data see 
13
 and 
14
. Effect sizes for the SNPs that reached the given pT, along with 
the effect allele and associated rsID were extracted from these results. These SNP sets (one for each 
pT) were then extracted from the transplanted cohorts’ genotype data using PLINK’s extract 
function.  The genotype data was then pruned to remove SNPs in high linkage disequilibrium using 
PLINK with a 200kb sliding window, 10kb step size and r
2
 threshold of 0.25
34
. SCC PRS and BCC PRS 
were then calculated for each individual in our transplant cohorts using PLINK’s score function. In 
each cohort, PRSs were normalized to mean zero and standard deviation of one. 
 
2.4 Statistical analyses 
To evaluate the PRSs’ predictive value, they were tested as predictors of case: control status using 
logistic regression, and time to developing post-transplant NMSC using Cox proportional hazards 
models. Covariates included age at time of transplantation, era of transplant, site and the first eight 
PCs. Site was just included as a covariate for the Dublin-Glasgow analyses to account for the 
differences in obtaining NMSC status between the hospitals. Logistic regression was carried out 
using the glm function in R and Cox analysis was completed using the cox.ph function of the R 
survival package
35,36
. 
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To correct for multiple testing, we applied an approximate adjusted correction technique
37
. As the 
PRSs include subsets of the same overall group of SNPs, they are correlated. Bonferroni correction 
assumes tests are independent and therefore would be overly conservative. In this context, the 
following equation was applied
37
:                                         
Let Padj=adjusted p-value 
M=number of PRSs tested × number of phenotypes tested  
p(k)=unadjusted p-value for the given PRS score 
r(.k)=mean correlation among the outcomes other than outcome k 
After the p-values were adjusted for the number of PRSs tested using the above technique, further 
correction was applied to account for the three phenotypes being tested (NMSC, SCC and BCC) using 
Bonferroni correction.  
 
Beta coefficients were meta-analysed using the metafor R package
38
. The percentage of variation 
across the results from the different sites in the meta-analysis was accessed for heterogeneity using 
the I
2 
statistic
39
.  Receiver operator curves were calculated using the pROC package in R
40
. 
 
We performed decile analysis using the most significant PRS from the NMSC logistic regression (BCC 
pT1x10
-5
) and Cox analysis (SCC pT1x10
-5
). We merged the four datasets and divided samples into 
decile groups with the lowest polygenic load in the first decile and the highest PRS in the tenth 
decile.  Samples in each decile group were then compared to patients the first decile group and 
tested for association with NMSC using the previously described Cox and logistic regression analysis.  
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3. RESULTS 
Polygenic risk analysis was performed on 889 transplant recipients (567 males and 322 females), 239 
of whom developed any NMSC with 106 developing BCC and 150 developing SCC (see table 1) 
screened for European ancestry. Average time to developing NMSC was 2,837 days with a range 
from 91 to 7,343 days. In the total dataset, patients had a mean age of 47.3 years at time of 
transplantation and had an average follow-up (censoring at first skin cancer event, failure or death) 
of 9.0 years ranging from one to 10,398 days. During this follow-up period, there were 243 graft 
failures with an average of 6.7 years to graft failure. Patients demonstrated a one, five and ten-year 
graft survival of 95.4%, 85.8% and 65.3% respectively.  
 
In order to facilitate a comprehensive assessment of PRSs on post-transplant NMSC we first set out 
to identify the clinical variables influencing NMSC status in a post-transplant setting. In this context, 
we analysed age at time of transplantation, sex, era of transplant and azathioprine exposure using a 
logistic regression and Cox regression approach (see methods section). These were tested against 
NMSC, as well as the two main subtypes of NMSC: BCC and SCC to evaluate subtype specific 
differences. Age alone was found to be a significant predictor of NMSC, BCC and SCC in both the Cox 
and logistic regression analyses (see table 2) and was brought forward as a covariate in our analyses. 
Although era of transplantation was not a significant predictor of skin cancer, we felt it was 
appropriate to include it as a covariate as to account for differences in immunosuppression regimens 
which are known to influence the onset of NMSC post-transplant
41
. 
 
 
To investigate the impact of PRS on time to NMSC, we carried out a Cox proportional hazards 
analysis adjusting for age, era, eight PCs and clinical centre for transplantation (site) where 
appropriate (see methods section). The Cox analysis was carried out separately for each site and 
then meta-analysed across sites. Analysing the impact of SCC and BCC PRS on case: control status of 
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NMSC, we observed a number of PRSs significantly associated with time-to-event and case: control 
status of NMSC, BCC and SCC post-transplant (see table 3).   
 
SCC pT1x10
-5
 PRS was the most significant predictor of time to NMSC post-transplant and BCC 
pT1x10
-5
 PRS was the most significant predictor of NMSC post-transplant case: control status, with a 
number of other SCC and BCC PRSs at different p-value thresholds also reaching significance. There 
was a large degree of overlap in the SNPs that reached pT1x10
-5 
in BCC and SCC GWASs
13,14
, with 69% 
of the SNPs in the SCC PRS found in the BCC PRS at this threshold (see Table S1 and S2 for SNPs used 
for these scores). This overlap is consistent with our finding that both SCC and BCC PRSs were 
significant of time to and case:control status of NMSC. Figure 1 illustrates how an increase in SCC 
pT1x10
-5
 PRS leads to a faster time to developing NMSC. This effect was consistent across cohorts 
and the same trend was seen in the BCC and SCC sub analyses (see table 3). 
 
Increased BCC pT1x10
-5
 PRS correlated with an increased risk of developing NMSC within the first ten 
years’ post-transplant (see table 3). The afore-mentioned most significant results all had an I2 of 0% 
indicating there was low heterogeneity across the variation of results at the different sites.  
 
For the most significant PRS in the Cox and logistic NMSC analysis, we performed a decile analysis 
whereby samples in each decile group were compared to patients the first (lowest) decile group and 
tested for association with NMSC (see table 4). For this and for the proceeding receiver operator 
curve and concordance analyses we merged the three cohorts prior to analysing association with 
NMSC. We found that for each decile group, the lower PRS subset associated with lower risk of 
NMSC post-transplant and reduced time to NMSC post-transplant, with the highest polygenic load 
(10
th
 decile) group having a hazard ratio of 3.11 when compared to the first decile group.  
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To access the potential clinical applicability of the significant PRSs previously described, we 
performed a comparative receiver operator curve analysis that determined the area under the 
curves for the different predictive models (see figure 2). The most predictive model was the full 
model, which included age, site, era, SCC pT1x10
-5
 PRS and PCs. The area under the curve for the 
clinical model (which included ‘age’, ‘era’ and ‘site’) was 0.786 compared with 0.813 for the full 
model (which included ‘age’, ‘era’, ‘site’, ‘PRS’ and ‘PCs’) indicating that the genetic factors 
contribute additional predictive value. The area under the curve when PCs were excluded from the 
full model, leaving just clinical covariates and PRS, was 0.799. The PRS alone, without additional 
covariates, had an area under the curve of 0.60. To analyse the predictive value of the PRS in our Cox 
analysis of time to developing NMSC post-transplant we compared the concordance statistic (c-stat) 
of the full model (which included ‘age’, ‘era’, ‘site’, ‘PRS’ and ‘PCs’)  to the clinical model (‘age’, ‘era’ 
and ‘site’).  The c-stat measures the proportion of pairs of individuals in which the individual with the 
higher-risk predictor developed NMSC before the individual with the lower-risk predictor. We found 
that found the genetic component added additional predictive value when predicting time to NMSC 
post-transplant with a larger c-stat for the full model (0.74) compared to the clinical model (0.71) 
with the PRS contributing 0.02 and the PCs contributing 0.01. 
4. DISCUSSION 
Our findings show a significant association between polygenic effects of variants associated with NMSC in the 
general population and post-transplant NMSC. We found that individuals with increased polygenic risk for BCC 
and SCC as determined from a previous non-transplant GWAS had both increased risk of NMSC and faster time 
to NMSC post-transplant respectively. This effect was consistent across three different cohorts in over 800 
patients. We found the most significant PRS in our NMSC Cox analysis was that at pT1x10
-5
 indicating that 
signals that are below the genome-wide significance threshold (5x10
-8
) are contributing to the speed at which 
individuals develop NMSC after transplantation.   
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To analyse the potential clinical application of this work, we compared the area under the curve of 
the full model, which included PRS to that with only the clinical variables for predicting case: control 
status of NMSC. The full model had a larger area under the curve than the model with clinical 
variables alone indicating the PRS is adding some positive predictive value to the model. Similarly, 
for the Cox analysis we compared the concordance statistics of the model with and without the PRS. 
Again, the PRS had additional predictive value beyond that explained by clinical variables. Although 
clinical variables have a large impact on the development of NMSC post-transplant, there is 
unexplained risk, and with the addition of the PRS we do get increased predictive value (albeit 
modest, 0.02 of the concordance explained by PRS).  
 
Knowledge of a patient’s genetic risk of certain conditions could help clinicians to best determine 
what drugs would best suit what patients. Polygenic risk scores are reasonably cheap and easy to 
implement, with GWAS genotyping now costing less than €100 per individual. A recent study 
demonstrated the potential clinical utility of PRS in patients with bipolar affective disorder to stratify 
those who were at higher risk of non-response to lithium, finding that those with a high PRS for 
schizophrenia had a greater increased risk of non-response to lithium
42
. In transplant patients, 
clinicians have the option to tailor patients’ immunosuppression regimens and select from a number 
of different immunosuppressant treatments
43
. Incorporating PRSs for multiple outcomes such as 
post-transplant diabetes, cardiovascular risk as well as other forms of malignancy could allow for 
more accurate prediction of the risks for an individual patient on a specific treatment regime. For 
example, switching patients to sirolimus has been demonstrated to reduce risk of post-transplant 
skin cancer
44. The knowledge of a patient’s polygenic risk of skin cancer post-transplant could also 
inform less drastic interventions such as frequency of checks with dermatologists and may also 
increase a patient’s likelihood to take on board lifestyle interventions such as wearing sunscreen and 
carrying out regular skin checks. This being said, although highly significant, the effect size of the PRS 
found in this study is relatively small and therefore only those in the top deciles of the distribution of 
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polygenic burden (see table 4) could realistically benefit from interventions based on their PRS. 
However, this study is the first of its kind to look at GWAS based PRS in a transplant setting and is 
proof of concept of the potential clinical utility of these kinds of scores in transplant populations. 
The integration of genetic knowledge in the clinic could allow for more personalised post-transplant 
treatment regimens in the future and even get us one step closer to tolerant transplantations.  
 
PRSs have the potential to inform clinical care through the identification of patients at high genetic 
risk for a certain condition. This could inform not only therapeutic interventions but also patient’s 
lifestyle choices and the frequency/need for disease screening
45
. However, PRSs have a number of 
limitations in this setting. Firstly, there is a higher level of uncertainty around the levels of risk 
predicted by a PRS compared to risk estimates based on familial genetic variant screening (such as 
screening for BRCA1/2 alleles)
45
. Also, PRS have yet to fully incorporate rare variants, which may 
change an individual’s PRS. Communication of polygenic risk is also a major obstacle in their 
application for clinical care. It is vital that patients and clinicians are fully aware of what a risk 
determined via a PRS really means for the patient’s prognosis45. 
 
Our study had a number of limitations. Firstly, a number of clinical variables were unavailable 
including sun exposure or full immunosuppressant treatment data (such as dosage or changes in 
immunosuppression over time). Therefore, some of the unexplained variance from our models may 
have been characterised if there was more extensive clinical data available. This may have also lead 
to some confounding between the different cohorts as the Tennessee cohort was predominantly 
receiving tacrolimus whereas the Dublin/Glasgow and Belfast groups were predominantly treated 
with cyclosporine. However, we did attempt to control for this effect by including era of 
transplantation as a covariate in our analyses as different eras would have a predominant 
immunosuppression treatment regime. Previous studies have shown that NMSC risk is greater in 
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those treated with cyclosporine compared to tacrolimus treated patients
46
. However, we did not see 
a large amount of heterogeneity between the sites in the I
2
 analysis. 
 
Secondly, we cannot tell if the effect of PRS on skin cancer detected here is different from that 
expected within a non-transplant population. It is possible the predictive value we see in this 
transplant population is identifying those individuals at high risk of skin cancer regardless of setting. 
In this context, the study was limited by the lack of a non-screened population to test for difference 
in the effect size of PRS, across transplant and non-transplant populations. For this reason, we 
cannot say whether this effect is specific to post-transplant NMSC or applicable to NMSC in general 
nor can we determine if the effect is immunosuppression related. Further work will be required to 
answer this important question.  
 
Finally, this study was done a homogenous European population and so further work is required to 
assess the predictive ability of this risk score in other more diverse, non-European populations. The 
alleles used to calculate the PRS were taken from two European GWA studies. For accurate 
interpretation of polygenic risk of NMSC in non-European populations a GWAS ethnically matched to 
the population being studied should be used to select alleles
47
.  
 
In conclusion, we have illustrated that PRS can be used to predict case: control status of, and time to 
NMSC from the time of transplantation. We found that the PRS provides limited, but significant 
predictive value beyond what clinical variables alone can explain. As transplant populations are 
exposed to immunosuppression, surgery and, in most cases, long term chronic disease common 
genetic variants that may have small effects in the general population may have increased effects in 
these screened populations. Therefore, the utility of PRS in transplant settings could be a useful tool 
both clinically and for discovery of new biological mechanisms involved in transplant outcomes.  
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FIGURE LEGENDS 
Figure 1. SCC pT1x10
-5
 as a predictor of time to developing NMSC post-transplant 
Weight= proportion of data the given site contributed to overall model; coef [95% CI] = effect size 
with lower and upper 95% confidence intervals. Z_SCC_pT_0.00001 = normalized PRS of SCC at p 
value threshold 0.00001, RE model = Random effects model, models were adjusted for age, 
recruitment site, 8 PCs and era of transplantation (pre-2000 vs post-2000). 
 
Figure 2. Comparison of area under the curve in the logistic regression analysis 
Genetic model = Polygenic Risk Score (PRS) and first eight principal components (8 PCs); clinical 
model = age, era and site; Full model = PRS, first 8 PCs, age, era and site 
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TABLES 
 
 
Table 1. Summary statistics of total dataset 
Stdev = standard deviation, No. (%) male – Total/Cases/Controls = Number (and percentage) of 
males in total cohort, cases only and controls only, NMSC=non-melanoma skin cancer, SCC = 
squamous cell carcinoma, BCC= basal cell carcinoma, Total N with skin cancer data = number of 
individuals with skin cancer data available for given skin cancer type 
  NMSC SCC BCC 
Total N with skin cancer data 889 593 549 
Number of events 239 150 106 
Average days to event (stdev) 2837 (1920) 2897 (1927) 3314 (2121) 
Average days of follow-up in controls (stdev) 3456 (1881) 3387 (1854) 3387 (1854) 
No. (%) male - Total  567 (64%) 371 (63%) 343 (62%) 
No. (%) male - Cases 165 (69%) 105 (70%) 77 (73%) 
No. (%) male - Controls 402 (62%) 266 (60%) 266 (60%) 
Average age (years) at transplant (stdev) - 
Total 
47.27 (14.37) 48.72 (14.44) 47.99 (14.39) 
Average age (years) at transplant (stdev) - 
Cases 
52.26 (12.79) 54.19 (12.56) 52.69 (12.58) 
Average age (years) at transplant (stdev) - 
Controls 
45.44 (14.49) 46.86 (14.58) 47.01 (14.69) 
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Logistic 
 
NMSC SCC BCC 
Clinical 
Variable 
OR 
Lower 
CI 
Upper 
CI 
Pun Pbon OR 
Lower 
CI 
Upper 
CI 
Pun Pbon OR 
Lower 
CI 
Upper 
CI 
Pun Pbon 
Age 1.02 1.016 1.024 
2.56X10
-
12
 
3.07X10
-
11
 
1.02 1.01 1.03 3.27X10
-13
 
3.92X10
-
12
 
1.02 1.016 1.024 3.53X10
-14
 
4.24X10
-
13
 
Era 1.34 1.03 1.74 0.03 0.37 1.46 1.00 2.14 0.0521 0.63 1.50 0.89 2.51 0.1257 1 
Sex 0.85 0.76 0.96 0.007 0.08 0.84 0.75 0.95 0.005 0.06 0.90 0.79 1.02 0.09 1 
Azathioprine 1.13 0.95 1.34 0.18 1.00 1.11 0.93 1.32 0.24 1 1.11 0.91 1.34 0.32 1 
Cox 
 
NMSC SCC BCC 
Clinical 
Variable 
HR 
Lower 
CI 
Upper 
CI 
Pun Pbon HR 
Lower 
CI 
Upper 
CI 
Pun Pbon HR 
Lower 
CI 
Upper 
CI 
Pun Pbon 
Age 1.06 1.04 1.08 
3.35X10
-
24
 
4.02X10
-
23
 
1.07 1.05 1.09 3.85X10
-18
 
4.62X10
-
17
 
1.07 1.05 1.09 5.46X10
-13
 
6.55X10
-
12
 
Era 0.92 0.54 1.54 0.74 1.00 0.93 0.55 1.55 0.77 1 1.03 0.32 3.33 0.95 1 
Sex 0.65 0.47 0.91 0.01 0.12 0.64 0.45 0.91 0.01 0.12 1.57 0.72 3.43 0.31 1 
Azathioprine 2.23 1.04 4.78 0.04 0.48 3.06 0.84 11.17 0.09 1 0.76 0.44 1.32 0.33 1 
Table 2. Clinical meta-analyses results 
NMSC=non-melanoma skin cancer, SCC = squamous cell carcinoma, BCC= basal cell carcinoma, OR = odds ratio, HR= hazards ratio, Lower/Upper CI = 
lower/upper 95% confidence interval, Pun=uncorrected p value, Pbon=Bonferroni corrected p value (corrected for 12 tests). Estimate for sex is associated with 
females, OR/HR for age represents change in odds per year of age,   era = those who had transplant pre-2000 = 1 and those who had transplant from 2000 
onwards = 2.   
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Table 3. PRS logistic and Cox regression top results 
Meta-analysis results for logistic regression and Cox regression. Models were adjusted for age at 
time of transplant, era of transplant (pre-2000 vs 2000 onwards), recruitment site and the first 8 
principal components. (NMSC=non-melanoma skin cancer, SCC = squamous cell carcinoma, BCC= 
basal cell carcinoma, Top PRS = most significant polygenic risk score associated with given skin 
cancer in given model. OR = odds ratio, HR= hazards ratio, Lower/Upper CI = lower/upper 95% 
confidence interval, OR and HR based on 1 standard deviation increase in normalized PRS, 
Padj=approximate adjusted p value, Pbon=Bonferroni corrected p value (corrected for 36 tests); N = 
number of individuals tested 
  
Logistic 
Cancer 
Type 
Top PRS OR 
Lower 
CI 
Upper CI Padj Pbon 
N 
cases 
N 
NMSC BCC pT1x10
-5
 1.61 1.22 2.12 0.0022 0.03 165 438 
SCC SCC pT1x10
-9
 1.97 1.32 2.93 0.0023 0.03 100 283 
BCC SCC pT1x10
-6
 3.03 1.78 5.16 0.0001 0.0016 60 243 
Cox 
Cancer 
Type 
Top PRS HR 
Lower 
CI 
Upper CI Padj Pbon 
N 
events 
N 
NMSC SCC_pT1x10
-5
 1.41 1.24 1.61 
9.39E-
07 
1.29E-05 239 889 
SCC SCC_pT1x10
-6
 1.48 1.25 1.74 
9.35E-
06 
0.0001 150 593 
BCC SCC_pT1x10
-6
 1.67 1.35 2.06 5.5E-06 7.02E-05 106 549 
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Logistic 
Top PRS BCC pT0.00001 
PRS by decile OR Lower 
CI 
Upper 
CI 
P N N Cases 
2nd Decile 2.48 0.68 9.02 0.17 92 24 
3rd Decile 1.61 0.49 5.28 0.43 89 24 
4th Decile 2.20 0.76 6.35 0.15 94 31 
5th Decile 3.17 0.91 11.04 0.07 98 28 
6th Decile 1.32 0.40 4.38 0.65 101 26 
7th Decile 4.10 1.20 13.98 0.024 91 27 
8th Decile 6.06 1.67 21.92 0.006 96 34 
9th Decile 4.35 1.35 13.99 0.014 96 31 
10th Decile (highest) 5.22 1.65 16.57 0.005 89 36 
Cox 
Top PRS SCC pT0.00001 
PRS by decile HR Lower 
CI 
Upper 
CI 
P N N events 
2nd Decile 1.24 0.58 2.67 0.58 178 34 
3rd Decile 1.49 0.75 2.97 0.25 178 39 
4th Decile 2.09 1.00 4.35 0.049 178 41 
5th Decile 2.00 0.98 4.08 0.06 177 37 
6th Decile 1.90 0.93 3.87 0.08 178 42 
7th Decile 0.99 0.47 2.12 0.99 178 37 
8th Decile 1.83 0.93 3.61 0.08 178 43 
9th Decile 3.37 1.82 6.22 0.0001 178 55 
10th Decile (highest) 3.11 1.60 6.06 0.0008 177 47 
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Table 4. PRS logistic and Cox regression top results split by decile 
Samples in each decile group were compared to those in the first decile group (lowest PRS group). 
Analyses were adjusted for age, era of transplantation, geographic site and eight PCs.  SCC = 
squamous cell carcinoma, BCC= basal cell carcinoma, Top PRS = most significant polygenic risk score 
associated with given skin cancer in given model, pT = p-value threshold, OR = odds ratio, HR= 
hazards ratio, Lower/Upper CI = lower/upper 95% confidence interval, P= p value, N = number of 
individuals tested, N events = number of skin cancer events observed, N cases = number of individuals 
with non-melanoma skin cancer. 
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FIGURES 
 
Figure 1. SCC pT1x10
-5
 as a predictor of time to developing NMSC post-transplant 
Weight= proportion of data the given site contributed to overall model; coef [95% CI] = effect size 
with lower and upper 95% confidence intervals. Z_SCC_pT_0.00001 = normalized PRS of SCC at p 
value threshold 0.00001, RE model = Random effects model, models were adjusted for age, 
recruitment site, 8 PCs and era of transplantation (pre-2000 vs post-2000). 
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Figure 2. Comparison of area under the curve in the logistic regression analysis 
Genetic model = Polygenic Risk Score (PRS) and first eight principal components (8 PCs); clinical 
model = age, era and site; Full model = PRS, first 8 PCs, age, era and site 
 
